SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 838.10 |
| Enterprise Value ($M) | 1,264.86 |
| Book Value ($M) | 545.00 |
| Book Value / Share | 19.25 |
| Price / Book | 1.54 |
| NCAV ($M) | -367.02 |
| NCAV / Share | -13.01 |
| Price / NCAV | -2.28 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.26 |
| Return on Assets (ROA) | -0.16 |
| Return on Equity (ROE) | -0.34 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 0.88 |
| Current Ratio | 1.81 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 546.16 |
| Assets | 1,458.18 |
| Liabilities | 913.18 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | 0.00 |
| Net Income | 0.00 |
| Earnings Per Share Basic And Diluted | n/a |
| Earnings Per Share Diluted | n/a |
| Earnings Per Share Basic | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 0.00 |
| Cash from Investing | 0.00 |
| Cash from Financing | 0.00 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | Ameriprise Financial Inc | 6.30 | -29.26 | |
| 13G/A | BlackRock, Inc. | 7.10 | -14.81 | |
| 13D | Magnetar Financial LLC | 5.51 | ||
| 13G | BlackRock Portfolio Management LLC | 5.00 | ||
| 13G/A | Vanguard Group Inc | 5.64 | 0.00 | |
| 13G/A | Dimensional Fund Advisors Lp | 6.60 | -18.92 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 125,451 | 1,214,066 | 10.33 | |
| 67,598 | 1,003,514 | 6.74 | |
| 148,983 | 654,168 | 22.77 | |
| 58,329 | 554,285 | 10.52 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| QNCX – Quince Therapeutics, Inc. | QURE – uniQure N.V. |
| RARE – Ultragenyx Pharmaceutical Inc. | REGN – Regeneron Pharmaceuticals, Inc. |
| REPL – Replimune Group, Inc. |